DURHAM — Precision BioSciences is getting a new chief operating officer.
The genome-editing company based in Durham announced today that it has appointed David Thomson to fill the role.
He has previously served as the firm’s chief development officer since 2017.
“David has made a dramatic impact since joining Precision over two years ago, and I am delighted that he is taking on these new responsibilities at a critical time when we believe our pace of growth is accelerating, and our CAR T cancer immunotherapy, in vivo gene correction and food portfolios are progressing at pace,” Matt Kane, chief executive officer and co-founder of Precision BioSciences, said in a statement.
Back in July, the startup announced the opening of its highly prized production facility for in-house manufacturing of its unique technologies.
Calling it the Manufacturing Center for Advanced Therapeutics (MCAT), Precision touts the facility as “the first in-house current Good Manufacturing Process (cGMP)-compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf chimeric antigen receptor (CAR) T cell therapy products.”
Precision is developing product candidates in three innovative areas: its allogeneic CAR T immunotherapy, gene correction therapies, and, through its recent agricultural spinout, Elo Life Systems, food.
With the MCAT opening, Precision still has plenty of room to grow. It’s now leasing 17,300 square feet of its headquarters building, which contains 143,000 square feet of leasable space. The facility can allow the current staff of 10 to expand to 24 employees.
Durham’s Precision BioSciences opens manufacturing facility for geneome-edited products
